



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



V-0219 (hydrochloride)

Item No. 39740

CAS Registry No.: 2922283-73-4
Formal Name: 4-[[1-[[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]methyl]-3-piperidinyl]methyl]-morpholine, monohydrochloride
MF: C₂₀H₂₅F₃N₄O₂ • HCl
FW: 446.9
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

V-0219 (hydrochloride) is supplied as a solid. A stock solution may be made by dissolving the V-0219 (hydrochloride) in water. We do not recommend storing the aqueous solution for more than one day.

Description

V-0219 is a positive allosteric modulator (PAM) of the glucagon-like peptide 1 receptor (GLP-1R).¹ It is selective for GLP-1R over a panel of 54 other receptors, ion channels, and transporters at 10 μM. V-0219 (0.001-1 nM) potentiates GLP-1-induced cAMP accumulation in HEK293 cells expressing human GLP-1R. It also potentiates GLP-1-induced insulin secretion in INS-1E rat insulinoma cells, an effect that can be blocked by the GLP-1R antagonist exendin (9-39) amide. V-0219 improves glucose tolerance in wild-type, but not *Glp1r* knockout, mice when administered at a dose of 0.1 mg/kg and enhances a reduction in food intake induced by the GLP-1R agonist exendin-4 in rats at 0.001 mg/kg.

Reference

- Decara, J.M., Vázquez-Villa, H., Brea, J., *et al.* Discovery of V-0219: A small-molecule positive allosteric modulator of the glucagon-like peptide-1 receptor toward oral treatment for “diabesity”. *J. Med. Chem.* **65**(7), 5449-5461 (2022).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/21/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM